These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14509911)

  • 1. Is it too late to save Schering?
    Simons J
    Fortune; 2003 Sep; 148(5):145-6, 148, 150. PubMed ID: 14509911
    [No Abstract]   [Full Text] [Related]  

  • 2. Growing against the grain.
    Boyle M
    Fortune; 2004 May; 149(9):148-9, 152, 154 passim. PubMed ID: 15124331
    [No Abstract]   [Full Text] [Related]  

  • 3. Can J & J keep the magic going?
    Taylor A
    Fortune; 2002 May; 145(11):117-20, 122. PubMed ID: 12048959
    [No Abstract]   [Full Text] [Related]  

  • 4. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 5. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth.
    Stipp D
    Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884
    [No Abstract]   [Full Text] [Related]  

  • 7. For success, focus your strengths.
    Levinson AD
    Nat Biotechnol; 1998 May; 16 Suppl():45-6. PubMed ID: 9591268
    [No Abstract]   [Full Text] [Related]  

  • 8. From scandal to stardom: how Merck healed itself.
    Simons J
    Fortune; 2008 Feb; 157(3):94-6, 98. PubMed ID: 18335777
    [No Abstract]   [Full Text] [Related]  

  • 9. Advice for partnering with pharma.
    Howard K
    Nat Biotechnol; 2004 Nov; 22(11):1477-9. PubMed ID: 15586421
    [No Abstract]   [Full Text] [Related]  

  • 10. Row over industry link-up splits staff of Spanish lab.
    Fernandez Hermana LA
    Nature; 1994 Dec; 372(6507):586. PubMed ID: 7990935
    [No Abstract]   [Full Text] [Related]  

  • 11. The science-business tango. Interview by Mari Paul.
    Hirth P
    Nat Biotechnol; 2006 Aug; 24(8):1035-6. PubMed ID: 16900153
    [No Abstract]   [Full Text] [Related]  

  • 12. Merck's man in the hot seat.
    Simons J
    Fortune; 2004 Feb; 149(4):111-2, 114. PubMed ID: 14983668
    [No Abstract]   [Full Text] [Related]  

  • 13. The executive's role in ethics: the view from business and industry.
    Rossy GL
    Healthc Exec; 1987; 2(5):18-21. PubMed ID: 10302068
    [No Abstract]   [Full Text] [Related]  

  • 14. Ichan the spoiler.
    Creswell J
    Fortune; 2005 Mar; 151(6):195-6, 198. PubMed ID: 15782883
    [No Abstract]   [Full Text] [Related]  

  • 15. Developing customer databases.
    Rao SK; Shenbaga S
    Mark Health Serv; 2000; 20(4):10-4. PubMed ID: 11209474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IT solutions for big Pharma's big headache.
    Krohn R
    J Healthc Inf Manag; 2005; 19(1):13-5. PubMed ID: 15682670
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicine man. Interview by Richard M. Smith.
    Kindler J
    Newsweek; 2007 Apr; 149(16):E18. PubMed ID: 17561576
    [No Abstract]   [Full Text] [Related]  

  • 18. A new CEO'S RX for what ails Merck.
    Simons J
    Fortune; 2005 May; 151(11):28. PubMed ID: 15926519
    [No Abstract]   [Full Text] [Related]  

  • 19. Managing freedom: managing researchers as if they were warriors.
    Uitdehaag J
    Drug Discov Today; 2008 Jul; 13(13-14):555-7. PubMed ID: 18598909
    [No Abstract]   [Full Text] [Related]  

  • 20. Will R&D make Merck hot again?
    Simons J
    Fortune; 2002 Jul; 146(1):89-90, 92, 94. PubMed ID: 12119729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.